Despite the differential increase in TGR5 activation capacity by the two agonists, only the modest enterohepatic activation of TGR5 by INT-777, but not the robust activation by RO5527239, partially protected from NASH. Here, GPBAR1 is linked to metabolic dysfunction-associated steatohepatitis.